PCDH18 Polyclonal Antibody
Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND

Application
| WB, IHC-P, IHC-F, IF, ICC, E |
|---|---|
| Primary Accession | Q9HCL0 |
| Reactivity | Rat, Dog, Bovine |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 123 KDa |
| Physical State | Liquid |
| Immunogen | KLH conjugated synthetic peptide derived from human PCDH18 |
| Epitope Specificity | 381-480/1135 |
| Isotype | IgG |
| Purity | affinity purified by Protein A |
| Buffer | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| SUBCELLULAR LOCATION | Cell membrane. |
| SIMILARITY | Contains 6 cadherin domains. |
| Important Note | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| Background Descriptions | Protocadherins are a large family of cadherin-like cell adhesion proteins that are involved in the establishment and maintenance of neuronal connections in the brain. There are three protocadherin gene clusters, designated alpha, beta and gamma, all of which contain multiple tandemly arranged genes. PCDH18 (protocadherin 18), also known as PCDH68L, is a 1,135 amino acid single-pass type I cell membrane protein that contains six cadherin domains and a cytoplasmic tail that differs from classical cadherins. Expressed ubiquitously with highest expression in ovary and lung, PCDH18 interacts with Dab1 and functions as a potential calcium-dependent adhesion protein that may be involved in the establishment of cell-cell connections in the brain. Multiple isoforms of PCDH18 exist due to alternative splicing events. |
| Gene ID | 54510 |
|---|---|
| Other Names | Protocadherin-18, PCDH18, KIAA1562 |
| Target/Specificity | Expressed in all tissues, with highest expression in lung and ovary. |
| Dilution | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC=1:100-500,IF=1:100-500,ELISA=1:5000-10000 |
| Storage | Store at -20 ℃ for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 ℃. |
| Name | PCDH18 |
|---|---|
| Synonyms | KIAA1562 |
| Function | Potential calcium-dependent cell-adhesion protein. |
| Cellular Location | Cell membrane; Single-pass type I membrane protein |
| Tissue Location | Expressed in all tissues, with highest expression in lung and ovary. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.





Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.


